Search

Hydrogen peroxide

Hydrogen peroxide is an unstable compound in the presence of a base or catalyst, and is typically stored with a stabilizer in a weakly acidic solution. … Hydrogen peroxide is also considered as a generally recognized as safe compound by the FDA [L2024]; it is used as an antimicrobial agent in starch and cheese products, and as an oxidizing and reducing

Zenocutuzumab

[L51983] In May 2026, zenocutuzumab was granted additional approval by the US FDA for use in NRG1-positive cholangiocarcinoma. … [L56179] This approval was expedited following receipt of an FDA Commissioner’s National Priority Voucher.

Acetazolamide

It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual … Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition

Phenoxyethanol

According to the European Union Cosmetics Regulation (EC) n.1223/2009, phenoxyethanol is authorized as a preservative in cosmetic formulations at a maximum concentration of 1.0% [L2625]. … It is produced by reacting phenol (EU) and ethylene oxide (EU) at a high temperature and pressure. This substance occurs naturally in green tea (EU) [L2621].

Oxilofrine

Oxilofrine is used in combination with [DB11609] as an antitussive. It is currently marketed in Canada by Valeant under the tradename Cophylac.

Probenecid

Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.

Penpulimab

[A273848] In order to further reduce the risk of toxicities and improve efficacy, penpulimab was designed with Fc mutations in order to eliminate Fc receptor and complement-mediated effector function, … The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events.

Clostridium tetani

Rucaparib

[A249240] The drug was later approved by the European Commission in May 2018.[L42185] It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185]. … Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair.

Lenacapavir

[A244170, A244175, A244180, A244190] Lenacapavir was first globally approved on August 22, 2022 by the European Commission to treat adults with multi-drug resistant HIV infection. … [L42995] On December 22, 2022, it was also approved by the FDA.[L44473]